Cambridge’s Continuus Pharmaceuticals, a spinout of the Novartis-MIT Center for Continuous Manufacturing, has raised a Series A funding round of $2 million to commercialize its new manufacturing process for pharmaceuticals.
The process aims to be an alternative to the typical batch-wise, step-by-step processes typically used in drug manufacturing. The company’s continuous manufacturing process for small-molecule pharmaceuticals involves a single process for the synthesis of the active ingredient and the final dosage form.
Ultimately, the method aims to allow for on-demand manufacturing of pharmaceuticals. “Our end goal is to use our novel continuous manufacturing technology to provide patients with high quality and affordable medications faster,” co-founder and chief executive Salvatore Mascia said in an email.
The company also said it has executed an exclusive license on the technology with MIT.
The funding round was led by pharmaceutical equipment manufacturer Industria Macchine Automatiche.
An alum of the 2013 MassChallenge program, Continuus, whose other co-founder is Bayan Takizawa, is currently based at the Cambridge Innovation Center. The startup is seeking to move to a new development facility in Massachusetts in the near future to further develop its process, Mascia said.
Kyle Alspach has worked in journalism in Massachusetts since 2005 and was one of the original staff writers at BetaBoston.
Follow Kyle on Twitter